PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Sep 04, 2018

byncaipen

Ophthalmology | Transplants

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company...Read more

Aug 10, 2018

byncaipen

Ophthalmology

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.